Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Low grade ovarian cancer – clinical and molecular aspects

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
video not found
Published: 12.07.18
Views: 834

Dr Douglas Levine - NYU Langone Medical Center, New York, USA

Dr Levine speaks with ecancer at BCGS 2018 about low-grade serous carcinoma of the ovaries.

He highlights KRAS and BRAF mutations as markers of the disease, and targets for precision therapies.

Dr Levine also spoke with ecancer about immuno-oncology in SCCO, here.

Related videos

follow us

Immuno-oncology advances in cancer treatment e-learning

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation